How will you decide among the options of either carbo/gem>avelumab or checkpoint monotherapy for cisplatin-ineligible PD-L1 expressing urothelial carcinoma?
Given long term data from Keynote 052 for pembrolizumab presented at ASCO 2021.
What factors impact your treatment decisions?
For cis-ineligible PD-L1 negative patients, is there any role for checkpoint monotherapy given ORR ~20% in these patients on KN-052?
Answer from: Medical Oncologist at Community Practice
The KEYNOTE 052 data as well as other datasets support the idea that there are clearly a subset of previously-untreated cisplatin-ineligible metastatic urothelial cancer patients who receive benefit from front-line immunomonotherapy and can be treated with this approach. Importantly, responding pati...
Sign in or Register to read more